Latest News

FDA approves liso-cel, the first CAR T-cell therapy for relapsed marginal zone lymphoma, offering hope for improved patient outcomes.

Recent study results highlight the critical impact of comorbidities on survival rates in patients with melanoma, emphasizing the need for integrated cancer care strategies.

TARA-002 shows promising efficacy and safety in treating BCG-naive non-muscle invasive bladder cancer, with high response rates and durability.

A novel treatment shows promise for leptomeningeal disease in breast cancer, offering hope with improved survival rates and symptom relief.

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative biomarker-driven therapies.

JANX007 shows promising efficacy and manageable safety in treating metastatic castration-resistant prostate cancer, with significant PSA reductions and durable responses.

New phase 2 trial results reveal safusidenib's potential to significantly improve outcomes for patients with IDH1-mutant gliomas, offering hope for durable responses.

Pirtobrutinib receives FDA traditional approval for relapsed CLL, showing significant progression-free survival benefits in clinical trials.

New trial data reveals IGV-001 enhances overall survival in glioblastoma patients, marking a potential breakthrough in treatment options.

Ipatasertib shows promising efficacy in heavily pretreated patients with AKT1E17K mutations, highlighting its potential in diverse tumor types.

The FDA fast-tracks zotiraciclib for recurrent high-grade gliomas, offering hope for patients with IDH mutations and expanding treatment options.

Vorasidenib significantly reduces tumor growth rates in grade 2 glioma patients, improving progression-free survival and time to next intervention.

Naxitamab combined with GM-CSF shows promising results in treating high-risk neuroblastoma, achieving high response rates and manageable safety profiles.

A clinical trial of the menin inhibitor DS-1594b in patients with relapsed leukemia has been terminated due to inefficacy, revealing safety challenges and insights for future therapies.

A phase 1 study reveals that sequential CR7-GD2 CAR T-cell therapy administration is better tolerated in pediatric CNS tumor patients than concurrent methods.

Givastomig shows promising antitumor activity and a manageable safety profile in patients with CLDN18.2-positive gastroesophageal carcinoma.

In a recent phase 2 trial, TQB2102 showed promising antitumor activity and safety as a neoadjuvant therapy for HER2-positive breast cancer.

Discover the most anticipated abstracts at the 67th ASH Annual Meeting and Exposition, showcasing groundbreaking research in hematologic malignancies and innovative treatments.

During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

CLN-049 gains FDA fast track designation, offering hope for patients with relapsed/refractory AML through innovative immunotherapy solutions.

The FDA approves pegfilgrastim-unne, enhancing treatment options for cancer patients at risk of febrile neutropenia during chemotherapy.

The IsoPSA test revolutionizes prostate cancer diagnosis, enhancing risk assessment and reducing unnecessary biopsies for men with elevated PSA levels.

New research from ESMO 2025 reveals significant survival benefits of intensified androgen blockade over traditional therapies for advanced prostate cancer.

Tovorafenib shows promising long-term efficacy for pediatric low-grade glioma, with significant treatment-free intervals and manageable safety profile.

New findings from the TEM-GBM study reveal promising survival rates for patients with glioblastoma treated with the experimental gene therapy Temferon.

A study reveals cabozantinib plus nivolumab shows a 71% response rate in fumarate hydratase-deficient renal cell carcinoma, promising survival outcomes.

The OptiTROP-Lung05 trial shows promising results for sacituzumab tirumotecan combined with pembrolizumab in treating advanced non–small cell lung cancer.

November 2025 marks a transformative month for oncology, featuring groundbreaking FDA approvals that enhance treatment options across various cancer types.

Recent study results confirm that the venetoclax and obinutuzumab combination is a cost-effective treatment for patients with chronic lymphocytic leukemia in Canada.

Emerging research highlights the challenges and potential of ctDNA in managing minimal residual disease in breast cancer, paving the way for innovative treatment strategies.

Axi-cel shows impressive long-term efficacy in treating relapsed/refractory indolent non-Hodgkin lymphoma, with potential curative outcomes for patients.